Restoring Mortality Data in the FOURIER Cardiovascular Outcomes Trial of Evolocumab in Patients with Cardiovascular Disease: A Reanalysis Based on Regulatory Data

Juan Erviti et al. The FOURIER trial showed a bene t of the PCSK9 inhibitor evolocumab over placebo with respect to cardiovascular outcomes in patients with cardiovascular disease. However, we observed some inconsistencies between the information in the Clinical Study Report (CSR) and that in the 2017 primary trial results publication. We aimed to restore […]